Lead
New global research shows that roughly one-quarter of healthy life years lost to breast cancer are attributable to modifiable lifestyle risks such as high red meat intake and tobacco exposure. The analysis, drawing on cancer-registry data from more than 200 countries between 1990 and 2023, also projects a substantial rise in new cases by 2050. Globally, new female breast cancer diagnoses are expected to grow from 2.3 million in 2023 to more than 3.5 million by 2050. In high-income settings screening and treatment have limited some harms, but the study warns the burden is shifting toward lower-income regions with later diagnosis and higher mortality.
Key takeaways
- Approximately 28% of the global breast cancer burden in 2023—about 6.8 million years of healthy life lost—was linked to six potentially modifiable risk factors.
- High red meat consumption was the largest single contributor, associated with nearly 11% of healthy years lost to breast cancer in 2023.
- Tobacco use, including secondhand smoke, accounted for around 8% of the 2023 burden; high fasting blood glucose for 6%; high BMI for 4%; and both high alcohol use and low physical activity about 2% each.
- Incidence in women aged 20–54 rose by roughly 29% since 1990, while rates in women 55 and older remained relatively stable; in 2023 incidence was 161 per 100,000 in those 55+ versus 50 per 100,000 in ages 20–54.
- Global new female breast cancer cases are forecast to increase by about one third from 2.3 million (2023) to over 3.5 million by 2050, driven largely by demographic change and rising incidence in younger women.
- One in seven women in the UK is expected to develop breast cancer in her lifetime under current trends.
Background
The findings come from the Global Burden of Disease (GBD) Breast Cancer Collaborators and were published in Lancet Oncology, using registry data spanning 1990–2023 from more than 200 countries. The GBD framework quantifies disease burden in years lived with disability, years lost to premature mortality, and combines these into disability-adjusted life years (DALYs), here reported as “years of healthy life lost.”
Breast cancer epidemiology has shifted over recent decades: increases in incidence in younger age groups have been reported in many settings, while improved screening and treatment in wealthier countries have reduced mortality and prolonged survival. Health systems, access to early diagnosis, and availability of comprehensive treatment are critical determinants of outcomes, and gaps remain wide between high-income and lower-income regions.
Main event
The study’s central result is that 28% of breast-cancer-related healthy life years lost in 2023 were attributable to six modifiable exposures. High red meat intake was identified as the largest single risk factor in global attributable burden, followed by tobacco exposure. The research team combined population-based cancer registries with exposure and risk-estimate data to produce regional and global estimates and to model future trends to 2050.
Age-patterns reported in the analysis show that women aged 55 and older still account for the majority of cases, with an incidence of 161 per 100,000 in 2023, compared with 50 per 100,000 in women aged 20–54. However, the younger group’s incidence has climbed nearly 29% since 1990, indicating shifting risk profiles and exposures among younger cohorts.
The collaborators also produced projections to 2050: new female breast cancer cases are forecast to rise from 2.3 million in 2023 to more than 3.5 million by 2050. The authors note that demographic change (population growth and aging) plus rising incidence in younger women are the main drivers of the projected increase.
Analysis & implications
The attribution of more than a quarter of the global breast-cancer burden to modifiable lifestyle factors underscores prevention’s potential role alongside screening and treatment. If associations are causal, population-level reductions in red meat consumption, smoking prevalence, excess body weight, alcohol intake, and improvements in physical activity could meaningfully lower future DALYs.
Policy implications differ by setting. In high-income countries, sustained screening coverage and advances in therapy have improved outcomes but prevention could reduce incidence and health-system costs. In lower-income countries where late-stage presentation and limited treatment capacity drive mortality, combining prevention with investments in early detection and care is essential to avoid widening disparities.
Economically, lowering exposure to these risks could yield health system savings and productivity gains, but effective interventions require multisectoral action—food policy, tobacco control, diabetes prevention, urban planning for activity, and alcohol regulation. The study’s projections to 2050 also highlight that delay in action will make reversing the trend more difficult and more costly.
Comparison & data
| Metric | Value (2023) | Projection (2050) |
|---|---|---|
| New female cases (global) | 2.3 million | >3.5 million |
| Incidence, age 55+ | 161 per 100,000 | — |
| Incidence, age 20–54 | 50 per 100,000 (29% rise since 1990) | — |
| Attributable DALYs linked to modifiable risks | 6.8 million years (28%) | — |
The table summarizes the headline numbers used throughout the analysis. The 6.8 million figure refers to years of healthy life lost globally in 2023 attributable to six modifiable exposures. The projection to 2050 reflects demographic change and the modeled trends in incidence; uncertainty intervals around these projections were reported in the original study and should be consulted for policy use.
Reactions & quotes
Advocacy and research groups emphasized both the human cost and the policy opportunities highlighted by the study.
“Breast cancer continues to take a profound toll on women’s lives and communities, and the burden is shifting to settings with less access to timely diagnosis and quality care,”
Kayleigh Bhangdia, IHME (lead author)
The lead author’s remark places the findings in the context of global inequities in cancer care and outcomes.
“We are determined to ensure that by 2050 everyone with breast cancer can live and live well,”
Claire Rowney, Breast Cancer Now (charity)
Breast Cancer Now framed the results as a call for combined action on prevention, research, and global collaboration.
“Prevention remains a key way to reduce rates—many cases are linked to smoking, overweight and alcohol,”
Sophie Brooks, Cancer Research UK (health information manager)
Cancer Research UK reiterated prevention’s importance alongside detection and treatment improvements.
Unconfirmed
- The extent to which each listed risk factor has a strictly causal effect versus being a marker for other underlying exposures varies by region and individual study—causality is stronger for some factors than others.
- Projections to 2050 depend on assumptions about future exposures, screening uptake, and treatment improvements; real-world deviations (policy changes, new therapies) could alter the forecast substantially.
- Data quality varies across countries and registries; under-ascertainment in some low-income settings could bias regional burden estimates.
Bottom line
This large, multi-country analysis quantifies the substantial role of modifiable lifestyle factors in the global breast cancer burden and projects a sizeable increase in new cases by 2050. The evidence suggests that prevention—reducing red meat consumption, tobacco exposure, excess blood glucose and weight, alcohol use, and promoting activity—could avert a meaningful portion of future healthy years lost.
Yet prevention alone will not close global gaps: equitable access to early diagnosis and effective treatment remains essential, especially in low- and lower middle-income countries where the burden is shifting. Policymakers should combine population-level prevention strategies with investments in cancer detection and care to reduce both incidence and mortality over the coming decades.
Sources
- The Guardian (news report summarising the study; media)
- Lancet Oncology (academic journal; original study published here)
- Institute for Health Metrics and Evaluation (IHME) (research institute; GBD collaborators and data methodology)
- Breast Cancer Now (charity; reaction)
- Cancer Research UK (research charity; context on preventable cases)